Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy
DeWitt, Judy Park
Yuan, ZhongqinNote: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationYang, Z., Z. Su, J. P. DeWitt, L. Xie, Y. Chen, X. Li, L. Han, et al. 2017. “Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy.” EBioMedicine 19 (1): 49-59. doi:10.1016/j.ebiom.2017.04.017. http://dx.doi.org/10.1016/j.ebiom.2017.04.017.
AbstractBone is one of the most preferred sites of metastasis in lung cancer. Currently, bisphosphonates and denosumab are major agents for controlling tumor-associated skeletal-related events (SREs). However, both bisphosphonates and denosumab significantly increase the risk for jaw osteonecrosis. Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and the most frequently prescribed cholesterol-lowering agents, have been reported to inhibit tumor progression and induce autophagy in cancer cells. However, the effects of statin and role of autophagy by statin on bone metastasis are unknown. In this study, we report that fluvastatin effectively prevented lung adenocarcinoma bone metastasis in a nude mouse model. We further reveal that fluvastatin-induced anti-bone metastatic property was largely dependent on its ability to induce autophagy in lung adenocarcinoma cells. Atg5 or Atg7 deletion, or 3-methyadenine (3-MA) or Bafilomycin A1 (Baf A1) treatment prevented the fluvastatin-induced suppression of bone metastasis. Furthermore, we reveal that fluvastatin stimulation increased the nuclear p53 expression, and fluvastatin-induced autophagy and anti-bone metastatic activity were mostly dependent on p53.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:33029905
- HMS Scholarly Articles